156 related articles for article (PubMed ID: 23219325)
1. Novel cinnoline-based inhibitors of LRRK2 kinase activity.
Garofalo AW; Adler M; Aubele DL; Bowers S; Franzini M; Goldbach E; Lorentzen C; Neitz RJ; Probst GD; Quinn KP; Santiago P; Sham HL; Tam D; Truong AP; Ye XM; Ren Z
Bioorg Med Chem Lett; 2013 Jan; 23(1):71-4. PubMed ID: 23219325
[TBL] [Abstract][Full Text] [Related]
2. Triazolopyridazine LRRK2 kinase inhibitors.
Franzini M; Ye XM; Adler M; Aubele DL; Garofalo AW; Gauby S; Goldbach E; Probst GD; Quinn KP; Santiago P; Sham HL; Tam D; Truong A; Ren Z
Bioorg Med Chem Lett; 2013 Apr; 23(7):1967-73. PubMed ID: 23454015
[TBL] [Abstract][Full Text] [Related]
3. Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold.
Galatsis P; Henderson JL; Kormos BL; Han S; Kurumbail RG; Wager TT; Verhoest PR; Noell GS; Chen Y; Needle E; Berger Z; Steyn SJ; Houle C; Hirst WD
Bioorg Med Chem Lett; 2014 Sep; 24(17):4132-40. PubMed ID: 25113930
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors.
Garofalo AW; Adler M; Aubele DL; Brigham EF; Chian D; Franzini M; Goldbach E; Kwong GT; Motter R; Probst GD; Quinn KP; Ruslim L; Sham HL; Tam D; Tanaka P; Truong AP; Ye XM; Ren Z
Bioorg Med Chem Lett; 2013 Apr; 23(7):1974-7. PubMed ID: 23453068
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2.
Troxler T; Greenidge P; Zimmermann K; Desrayaud S; Drückes P; Schweizer T; Stauffer D; Rovelli G; Shimshek DR
Bioorg Med Chem Lett; 2013 Jul; 23(14):4085-90. PubMed ID: 23768909
[TBL] [Abstract][Full Text] [Related]
6. Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond.
Göring S; Taymans JM; Baekelandt V; Schmidt B
Bioorg Med Chem Lett; 2014 Oct; 24(19):4630-4637. PubMed ID: 25219901
[TBL] [Abstract][Full Text] [Related]
7. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
Deng X; Choi HG; Buhrlage SJ; Gray NS
Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
[TBL] [Abstract][Full Text] [Related]
8. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor.
Henderson JL; Kormos BL; Hayward MM; Coffman KJ; Jasti J; Kurumbail RG; Wager TT; Verhoest PR; Noell GS; Chen Y; Needle E; Berger Z; Steyn SJ; Houle C; Hirst WD; Galatsis P
J Med Chem; 2015 Jan; 58(1):419-32. PubMed ID: 25353650
[TBL] [Abstract][Full Text] [Related]
9. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
Kethiri RR; Bakthavatchalam R
Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
[TBL] [Abstract][Full Text] [Related]
10. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
[TBL] [Abstract][Full Text] [Related]
11. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations.
Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H
Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745
[TBL] [Abstract][Full Text] [Related]
12. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological inhibition of LRRK2 cellular phosphorylation sites provides insight into LRRK2 biology.
Zhao J; Hermanson SB; Carlson CB; Riddle SM; Vogel KW; Bi K; Nichols RJ
Biochem Soc Trans; 2012 Oct; 40(5):1158-62. PubMed ID: 22988882
[TBL] [Abstract][Full Text] [Related]
14. A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease Using RapidFire Mass Spectrometry.
Leveridge M; Collier L; Edge C; Hardwicke P; Leavens B; Ratcliffe S; Rees M; Stasi LP; Nadin A; Reith AD
J Biomol Screen; 2016 Feb; 21(2):145-55. PubMed ID: 26403521
[TBL] [Abstract][Full Text] [Related]
15. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.
Fell MJ; Mirescu C; Basu K; Cheewatrakoolpong B; DeMong DE; Ellis JM; Hyde LA; Lin Y; Markgraf CG; Mei H; Miller M; Poulet FM; Scott JD; Smith MD; Yin Z; Zhou X; Parker EM; Kennedy ME; Morrow JA
J Pharmacol Exp Ther; 2015 Dec; 355(3):397-409. PubMed ID: 26407721
[TBL] [Abstract][Full Text] [Related]
16. Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors.
Estrada AA; Sweeney ZK
J Med Chem; 2015 Sep; 58(17):6733-46. PubMed ID: 25915084
[TBL] [Abstract][Full Text] [Related]
17. GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.
Reith AD; Bamborough P; Jandu K; Andreotti D; Mensah L; Dossang P; Choi HG; Deng X; Zhang J; Alessi DR; Gray NS
Bioorg Med Chem Lett; 2012 Sep; 22(17):5625-9. PubMed ID: 22863203
[TBL] [Abstract][Full Text] [Related]
18. Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors.
Greshock TJ; Sanders JM; Drolet RE; Rajapakse HA; Chang RK; Kim B; Rada VL; Tiscia HE; Su H; Lai MT; Sur SM; Sanchez RI; Bilodeau MT; Renger JJ; Kern JT; McCauley JA
Bioorg Med Chem Lett; 2016 Jun; 26(11):2631-5. PubMed ID: 27106707
[TBL] [Abstract][Full Text] [Related]
19. A novel GTP-binding inhibitor, FX2149, attenuates LRRK2 toxicity in Parkinson's disease models.
Li T; He X; Thomas JM; Yang D; Zhong S; Xue F; Smith WW
PLoS One; 2015; 10(3):e0122461. PubMed ID: 25816252
[TBL] [Abstract][Full Text] [Related]
20. Discovery of LRRK2 inhibitors using sequential in silico joint pharmacophore space (JPS) and ensemble docking.
Lang CA; Ray SS; Liu M; Singh AK; Cuny GD
Bioorg Med Chem Lett; 2015 Jul; 25(13):2713-9. PubMed ID: 25998502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
